Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

How to design a study to evaluate therapeutic drug monitoring in infectious diseases?

Märtson AG, Sturkenboom MGG, Stojanova J, Cattaneo D, Hope W, Marriott D, Patanwala AE, Peloquin CA, Wicha SG, van der Werf TS, Tängdén T, Roberts JA, Neely MN, Alffenaar JC.

Clin Microbiol Infect. 2020 Mar 20. pii: S1198-743X(20)30150-6. doi: 10.1016/j.cmi.2020.03.008. [Epub ahead of print] Review.

PMID:
32205294
2.

Development of a methodology to make individual estimates of the precision of liquid chromatography-tandem mass spectrometry drug assay results for use in population pharmacokinetic modeling and the optimization of dosage regimens.

Karvaly GB, Neely MN, Kovács K, Vincze I, Vásárhelyi B, Jelliffe RW.

PLoS One. 2020 Mar 5;15(3):e0229873. doi: 10.1371/journal.pone.0229873. eCollection 2020.

3.

Population Pharmacokinetics of Imipenem in Critically Ill Patients: A Parametric and Nonparametric Model Converge on CKD-EPI Estimated Glomerular Filtration Rate as an Impactful Covariate.

de Velde F, de Winter BCM, Neely MN, Yamada WM, Koch BCP, Harbarth S, von Dach E, van Gelder T, Huttner A, Mouton JW; COMBACTE-NET consortium.

Clin Pharmacokinet. 2020 Jan 20. doi: 10.1007/s40262-020-00859-1. [Epub ahead of print]

PMID:
31956969
4.

Determinants of Group B streptococcal virulence potential amongst vaginal clinical isolates from pregnant women.

Burcham LR, Spencer BL, Keeler LR, Runft DL, Patras KA, Neely MN, Doran KS.

PLoS One. 2019 Dec 18;14(12):e0226699. doi: 10.1371/journal.pone.0226699. eCollection 2019.

5.

Nonparametric Population Pharmacokinetic Modeling of Isoniazid in Colombian Patients With Tuberculosis.

Rodriguez CA, Zuluaga AF, Neely MN, Sierra Y, Morales-Gutierrez J, Zapata J, Zapata JD, Naranjo TW, Agudelo Y.

Ther Drug Monit. 2019 Dec;41(6):719-725. doi: 10.1097/FTD.0000000000000661.

PMID:
31725693
6.

Development of Chronic Pseudomonas aeruginosa-Positive Respiratory Cultures in Children with Tracheostomy.

Russell CJ, Simon TD, Neely MN.

Lung. 2019 Dec;197(6):811-817. doi: 10.1007/s00408-019-00285-6. Epub 2019 Oct 31.

PMID:
31673781
7.

Exposure of Larval Zebrafish to the Insecticide Propoxur Induced Developmental Delays that Correlate with Behavioral Abnormalities and Altered Expression of hspb9 and hspb11.

Shields JN, Hales EC, Ranspach LE, Luo X, Orr S, Runft D, Dombkowski A, Neely MN, Matherly LH, Taub J, Baker TR, Thummel R.

Toxics. 2019 Sep 21;7(4). pii: E50. doi: 10.3390/toxics7040050.

8.

Optimizing Gentamicin Dosing in Pediatrics Using Monte Carlo Simulations.

Alsultan A, Abouelkheir M, Elsharawy Y, Alkoraishi A, Osman R, Neely MN, Mansy W, Algahtani S.

Pediatr Infect Dis J. 2019 Apr;38(4):390-395. doi: 10.1097/INF.0000000000002120.

PMID:
30882729
9.

Early Use of Anti-influenza Medications in Hospitalized Children With Tracheostomy.

Miyakawa R, Barreto NB, Kato RM, Neely MN, Russell CJ.

Pediatrics. 2019 Mar;143(3). pii: e20182608. doi: 10.1542/peds.2018-2608.

10.

The Combination of Fosfomycin plus Meropenem Is Synergistic for Pseudomonas aeruginosa PAO1 in a Hollow-Fiber Infection Model.

Drusano GL, Neely MN, Yamada WM, Duncanson B, Brown D, Maynard M, Vicchiarelli M, Louie A.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e01682-18. doi: 10.1128/AAC.01682-18. Print 2018 Dec.

11.

Length of Stay and Hospital Revisit After Bacterial Tracheostomy-Associated Respiratory Tract Infection Hospitalizations.

Russell CJ, Mamey MR, Koh JY, Schrager SM, Neely MN, Wu S.

Hosp Pediatr. 2018 Jan 16. pii: hpeds.2017-0106. doi: 10.1542/hpeds.2017-0106. [Epub ahead of print]

12.

Interchangeability of Generic Drugs: A Nonparametric Pharmacokinetic Model of Gabapentin Generic Drugs.

Glerum PJ, Yu Y, Yamada WM, Neely MN, Maliepaard M, Burger DM, Neef C.

Clin Pharmacol Ther. 2018 Nov;104(5):966-973. doi: 10.1002/cpt.1023. Epub 2018 Feb 13.

13.

Risk factors for hospitalizations due to bacterial respiratory tract infections after tracheotomy.

Russell CJ, Thurm C, Hall M, Simon TD, Neely MN, Berry JG.

Pediatr Pulmonol. 2018 Mar;53(3):349-357. doi: 10.1002/ppul.23938. Epub 2018 Jan 4.

14.

The effect of medication nonadherence on progression-free survival among patients with renal cell carcinoma.

Shafrin J, Sullivan J, Chou JW, Neely MN, Doan JF, Maclean JR.

Cancer Manag Res. 2017 Nov 29;9:731-739. doi: 10.2147/CMAR.S148199. eCollection 2017.

15.

Prospective Trial on the Use of Trough Concentration versus Area under the Curve To Determine Therapeutic Vancomycin Dosing.

Neely MN, Kato L, Youn G, Kraler L, Bayard D, van Guilder M, Schumitzky A, Yamada W, Jones B, Minejima E.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e02042-17. doi: 10.1128/AAC.02042-17. Print 2018 Feb.

16.

Sofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants during SOF/LDV Combination Therapy against Genotype 1b Hepatitis C Virus (HCV).

Brown AN, Liu L, Rodriquez JL, Zhao L, Schuster L, Li E, Wang GP, Neely MN, Yamada W, Drusano GL.

Sci Rep. 2017 Oct 31;7(1):14421. doi: 10.1038/s41598-017-15007-2.

17.

Pharmacodynamics of teicoplanin against MRSA.

Ramos-Martín V, Johnson A, McEntee L, Farrington N, Padmore K, Cojutti P, Pea F, Neely MN, Hope WW.

J Antimicrob Chemother. 2017 Dec 1;72(12):3382-3389. doi: 10.1093/jac/dkx289.

PMID:
28962026
18.

Tools for the Individualized Therapy of Teicoplanin for Neonates and Children.

Ramos-Martín V, Neely MN, Padmore K, Peak M, Beresford MW, Turner MA, Paulus S, López-Herce J, Hope WW.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e00707-17. doi: 10.1128/AAC.00707-17. Print 2017 Oct.

19.

Quantifying Vibrio cholerae Enterotoxicity in a Zebrafish Infection Model.

Mitchell KC, Breen P, Britton S, Neely MN, Withey JH.

Appl Environ Microbiol. 2017 Aug 1;83(16). pii: e00783-17. doi: 10.1128/AEM.00783-17. Print 2017 Aug 15.

20.

Pseudomonas aeruginosa and post-tracheotomy bacterial respiratory tract infection readmissions.

Russell CJ, Simon TD, Mamey MR, Newth CJL, Neely MN.

Pediatr Pulmonol. 2017 Sep;52(9):1212-1218. doi: 10.1002/ppul.23716. Epub 2017 Apr 25.

21.

Correction for Rhodes et al., Evaluation of Vancomycin Exposures Associated with Elevations in Novel Urinary Biomarkers of Acute Kidney Injury in Vancomycin-Treated Rats.

Rhodes NJ, Prozialeck WC, Lodise TP, Venkatesan N, O'Donnell JN, Pais G, Cluff C, Lamar PC, Neely MN, Gulati A, Scheetz MH.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e00185-17. doi: 10.1128/AAC.00185-17. Print 2017 Apr. No abstract available.

22.

Is continuous infusion of imipenem always the best choice?

Suchánková H, Lipš M, Urbánek K, Neely MN, Strojil J.

Int J Antimicrob Agents. 2017 Mar;49(3):348-354. doi: 10.1016/j.ijantimicag.2016.12.005. Epub 2017 Feb 9.

PMID:
28189734
23.

The Zebrafish as a Model for Human Bacterial Infections.

Neely MN.

Methods Mol Biol. 2017;1535:245-266.

PMID:
27914084
24.

Population pharmacokinetics and pharmacodynamics of teicoplanin in neonates: making better use of C-reactive protein to deliver individualized therapy.

Ramos-Martín V, Neely MN, McGowan P, Siner S, Padmore K, Peak M, Beresford MW, Turner MA, Paulus S, Hope WW.

J Antimicrob Chemother. 2016 Nov;71(11):3168-3178. Epub 2016 Aug 19.

25.

A Nonparametric Pharmacokinetic Approach to Determine the Optimal Dosing Regimen for 30-Minute and 3-Hour Meropenem Infusions in Critically Ill Patients.

Mathew SK, Mathew BS, Neely MN, Naik GS, Prabha R, Jacob GG, K S, Fleming DH.

Ther Drug Monit. 2016 Oct;38(5):593-9. doi: 10.1097/FTD.0000000000000323.

PMID:
27454665
26.

Evaluation of Vancomycin Exposures Associated with Elevations in Novel Urinary Biomarkers of Acute Kidney Injury in Vancomycin-Treated Rats.

Rhodes NJ, Prozialeck WC, Lodise TP, Venkatesan N, O'Donnell JN, Pais G, Cluff C, Lamar PC, Neely MN, Gulati A, Scheetz MH.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):5742-51. doi: 10.1128/AAC.00591-16. Print 2016 Oct. Erratum in: Antimicrob Agents Chemother. 2017 Mar 24;61(4):.

27.

Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial.

Hope WW, Walsh TJ, Goodwin J, Peloquin CA, Howard A, Kurtzberg J, Mendizabal A, Confer DL, Bulitta J, Baden LR, Neely MN, Wingard JR; Blood and Marrow Transplant Clinical Trials Network.

J Antimicrob Chemother. 2016 Aug;71(8):2234-40. doi: 10.1093/jac/dkw127. Epub 2016 Apr 27.

28.

Animal Models of Streptococcus pyogenes Infection.

Watson ME Jr., Neely MN, Caparon MG.

In: Ferretti JJ, Stevens DL, Fischetti VA, editors. Streptococcus pyogenes : Basic Biology to Clinical Manifestations [Internet]. Oklahoma City (OK): University of Oklahoma Health Sciences Center; 2016-.
2016 Feb 10.

29.

An exploratory analysis of the ability of a cefepime trough concentration greater than 22 mg/L to predict neurotoxicity.

Rhodes NJ, Kuti JL, Nicolau DP, Neely MN, Nicasio AM, Scheetz MH.

J Infect Chemother. 2016 Feb;22(2):78-83. doi: 10.1016/j.jiac.2015.10.009. Epub 2015 Dec 17.

PMID:
26712584
30.

Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival.

Rhodes NJ, Kuti JL, Nicolau DP, Van Wart S, Nicasio AM, Liu J, Lee BJ, Neely MN, Scheetz MH.

Antimicrob Agents Chemother. 2015 Dec 14;60(3):1401-10. doi: 10.1128/AAC.01956-15.

31.

Optimal timing of oral fosfomycin administration for pre-prostate biopsy prophylaxis.

Rhodes NJ, Gardiner BJ, Neely MN, Grayson ML, Ellis AG, Lawrentschuk N, Frauman AG, Maxwell KM, Zembower TR, Scheetz MH.

J Antimicrob Chemother. 2015 Jul;70(7):2068-73. doi: 10.1093/jac/dkv067. Epub 2015 Mar 22.

PMID:
25802286
32.

Influence of renal function estimation on pharmacokinetic modeling of vancomycin in elderly patients.

Glatard A, Bourguignon L, Jelliffe RW, Maire P, Neely MN, Goutelle S.

Antimicrob Agents Chemother. 2015;59(6):2986-94. doi: 10.1128/AAC.04132-14. Epub 2015 Mar 9.

33.

Modification of the CpsA protein reveals a role in alteration of the Streptococcus agalactiae cell envelope.

Rowe HM, Hanson BR, Runft DL, Lin Q, Firestine SM, Neely MN.

Infect Immun. 2015 Apr;83(4):1497-506. doi: 10.1128/IAI.02656-14. Epub 2015 Feb 2.

34.

Combination treatment with meropenem plus levofloxacin is synergistic against Pseudomonas aeruginosa infection in a murine model of pneumonia.

Louie A, Liu W, VanGuilder M, Neely MN, Schumitzky A, Jelliffe R, Fikes S, Kurhanewicz S, Robbins N, Brown D, Baluya D, Drusano GL.

J Infect Dis. 2015 Apr 15;211(8):1326-33. doi: 10.1093/infdis/jiu603. Epub 2014 Oct 31.

35.

The Case for Using Higher Doses of First Line Anti-Tuberculosis Drugs to Optimize Efficacy.

Goutelle S, Bourguignon L, Maire P, Jelliffe RW, Neely MN.

Curr Pharm Des. 2014;20(39):6191-206. Review.

PMID:
25190098
36.

Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy.

Felton TW, Roberts JA, Lodise TP, Van Guilder M, Boselli E, Neely MN, Hope WW.

Antimicrob Agents Chemother. 2014 Jul;58(7):4094-102. doi: 10.1128/AAC.02664-14. Epub 2014 May 5.

37.

Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.

Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, Hope WW, Farkas A, Neely MN, Schentag JJ, Drusano G, Frey OR, Theuretzbacher U, Kuti JL; International Society of Anti-Infective Pharmacology and the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases.

Lancet Infect Dis. 2014 Jun;14(6):498-509. doi: 10.1016/S1473-3099(14)70036-2. Epub 2014 Apr 24. Review.

38.

Group B streptococcal serine-rich repeat proteins promote interaction with fibrinogen and vaginal colonization.

Wang NY, Patras KA, Seo HS, Cavaco CK, Rösler B, Neely MN, Sullam PM, Doran KS.

J Infect Dis. 2014 Sep 15;210(6):982-91. doi: 10.1093/infdis/jiu151. Epub 2014 Mar 11.

39.

Zebrafish as a model for zoonotic aquatic pathogens.

Rowe HM, Withey JH, Neely MN.

Dev Comp Immunol. 2014 Sep;46(1):96-107. doi: 10.1016/j.dci.2014.02.014. Epub 2014 Mar 6. Review.

40.

Differential expression and ligand binding indicate alternative functions for zebrafish polymeric immunoglobulin receptor (pIgR) and a family of pIgR-like (PIGRL) proteins.

Kortum AN, Rodriguez-Nunez I, Yang J, Shim J, Runft D, O'Driscoll ML, Haire RN, Cannon JP, Turner PM, Litman RT, Kim CH, Neely MN, Litman GW, Yoder JA.

Immunogenetics. 2014 Apr;66(4):267-79. doi: 10.1007/s00251-014-0759-4. Epub 2014 Jan 28.

41.

Zebrafish as a natural host model for Vibrio cholerae colonization and transmission.

Runft DL, Mitchell KC, Abuaita BH, Allen JP, Bajer S, Ginsburg K, Neely MN, Withey JH.

Appl Environ Microbiol. 2014 Mar;80(5):1710-7. doi: 10.1128/AEM.03580-13. Epub 2013 Dec 27.

42.

Transcriptional analysis of the Streptococcus pyogenes salivaricin locus.

Namprachan-Frantz P, Rowe HM, Runft DL, Neely MN.

J Bacteriol. 2014 Feb;196(3):604-13. doi: 10.1128/JB.01009-13. Epub 2013 Nov 15.

43.

Are vancomycin trough concentrations adequate for optimal dosing?

Neely MN, Youn G, Jones B, Jelliffe RW, Drusano GL, Rodvold KA, Lodise TP.

Antimicrob Agents Chemother. 2014;58(1):309-16. doi: 10.1128/AAC.01653-13. Epub 2013 Oct 28.

44.

Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation.

Åsberg A, Midtvedt K, van Guilder M, Størset E, Bremer S, Bergan S, Jelliffe R, Hartmann A, Neely MN.

Transpl Int. 2013 Dec;26(12):1198-207. doi: 10.1111/tri.12194. Epub 2013 Oct 15.

45.

Impact of Bolus dosing versus continuous infusion of Piperacillin and Tazobactam on the development of antimicrobial resistance in Pseudomonas aeruginosa.

Felton TW, Goodwin J, O'Connor L, Sharp A, Gregson L, Livermore J, Howard SJ, Neely MN, Hope WW.

Antimicrob Agents Chemother. 2013 Dec;57(12):5811-9. doi: 10.1128/AAC.00867-13. Epub 2013 Sep 3.

46.

Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients.

O'Connor L, Livermore J, Sharp AD, Goodwin J, Gregson L, Howard SJ, Felton TW, Schwartz JA, Neely MN, Harrison TS, Perfect JR, Hope WW.

J Infect Dis. 2013 Jul 15;208(2):351-61. doi: 10.1093/infdis/jit164. Epub 2013 Apr 18.

47.

Software for dosage individualization of voriconazole for immunocompromised patients.

Hope WW, Vanguilder M, Donnelly JP, Blijlevens NM, Brüggemann RJ, Jelliffe RW, Neely MN.

Antimicrob Agents Chemother. 2013 Apr;57(4):1888-94. doi: 10.1128/AAC.02025-12. Epub 2013 Feb 4.

48.

Innate immune response to Streptococcus iniae infection in zebrafish larvae.

Harvie EA, Green JM, Neely MN, Huttenlocher A.

Infect Immun. 2013 Jan;81(1):110-21. doi: 10.1128/IAI.00642-12. Epub 2012 Oct 22.

49.

Antiviral therapy of two patients with chromosomally-integrated human herpesvirus-6A presenting with cognitive dysfunction.

Montoya JG, Neely MN, Gupta S, Lunn MR, Loomis KS, Pritchett JC, Polsky B, Medveczky PG.

J Clin Virol. 2012 Sep;55(1):40-5. doi: 10.1016/j.jcv.2012.05.016. Epub 2012 Jul 5.

PMID:
22770640
50.

Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R.

Neely MN, van Guilder MG, Yamada WM, Schumitzky A, Jelliffe RW.

Ther Drug Monit. 2012 Aug;34(4):467-76. doi: 10.1097/FTD.0b013e31825c4ba6.

Supplemental Content

Loading ...
Support Center